Bristol-Myers beats forecasts, as hepatitis, cancer drugs deliver
July 28, 2016 at 07:03 AM EDT
July 28 (Reuters) - Bristol-Myers Squibb Co reported better than expected quarterly results, fueled by sales of its treatments for hepatitis C, cancer and blood clots, and slightly raised its full year profit forecast.